β -Glucan Improves Protective Qi Status in Adults with Protective Qi Deficiency—A Randomized, Placebo-Controlled, and Double-Blinded Trial
| Autor: | Rolando Lorenzo Maddela, Jin Li Chen, Xuan-Qiao Ou, Wei-Dong Yin, Robert Sinnott, Mark Levy, Ira Bernstein, Jun Wang, Jun-Rong Wu, Jian-Pin Shi, Jun-Qiang Tian, Hao-Jie Cheng |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
medicine.medical_specialty Saliva beta-Glucans Qi Double blinded 0211 other engineering and technologies 02 engineering and technology Traditional Chinese medicine Placebo 030226 pharmacology & pharmacy 03 medical and health sciences 0302 clinical medicine Double-Blind Method Risk Factors Internal medicine 021105 building & construction medicine Humans Pharmacology (medical) Glucan chemistry.chemical_classification Framingham Risk Score business.industry General Medicine medicine.disease Confidence interval Upper respiratory tract infection Complementary and alternative medicine chemistry Self Report business |
| Zdroj: | Chinese Journal of Integrative Medicine. 28:394-402 |
| ISSN: | 1993-0402 1672-0415 |
| DOI: | 10.1007/s11655-021-3444-0 |
| Popis: | To test the hypothesis that β -glucan enhances protective qi (PQi), an important Chinese medicine (CM) concept which stipulates that a protective force circulates throughout the body surface and works as the first line of defense against “external pernicious influences”. A total of 138 participants with PQi deficiency (PQD) were randomized to receive β -glucan (200 mg daily) or placebo for 12 weeks. Participants’ PQi status was assessed every 2 weeks via conventional diagnosis and a standardized protocol from which a PQD severity and risk score was derived. Indices of participants’ immune and general health status were also monitored, including upper respiratory tract infection (URTI), saliva secretory IgA (sIgA), and self-reported measures of physical and mental health (PROMIS). PQi status was not significantly different between the β -glucan and placebo treatment groups at baseline but improved significantly in the β -glucan (vs. placebo) group in a time-dependent manner. The intergroup differences [95% confidence interval (CI)] in severity score (scale: 1–5), risk score (scale: 0–1), and proportion of PQD participants (%) at finish line was 0.49 (0.35–0.62), 0.48 (0.35–0.61), and 0.36 (0.25–0.47), respectively. Additionally, β -glucan improved URTI symptom (scale: 1–9) and PROMIS physical (scale: 16.2–67.7) and mental (scale: 21.2–67.6) scores by a magnitude (95% CI) of 1.0 (0.21–1.86), 5.7 (2.33–9.07), and 3.0 (20.37–6.37), respectively, over placebo. β -glucan ameliorates PQi in PQD individuals. By using stringent evidence-based methodologies, our study demonstrated that Western medicine-derived remedies, such as β -glucan, can be employed to advance CM therapeutics. (ClinicalTrial.Gov registry: NCT03782974) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink